Published in Expert Rev Anti Infect Ther on June 01, 2007
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother (2010) 1.62
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg (2016) 1.55
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. World J Emerg Surg (2011) 1.29
A focus on intra-abdominal infections. World J Emerg Surg (2010) 1.10
Antibiotics in the clinical pipeline at the end of 2015. J Antibiot (Tokyo) (2016) 1.04
Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections. Infect Chemother (2016) 0.83
Canadian practice guidelines for surgical intra-abdominal infections. Can J Infect Dis Med Microbiol (2010) 0.83
Population Pharmacokinetics of Piperacillin in the Early Phase of Septic Shock: Does Standard Dosing Result in Therapeutic Plasma Concentrations? Antimicrob Agents Chemother (2015) 0.79
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Antimicrob Agents Chemother (2016) 0.78
Automated image analysis for quantification of filamentous bacteria. BMC Microbiol (2015) 0.77
Population pharmacokinetics of piperacillin in non-obese, obese and morbidly-obese critically ill patients. Antimicrob Agents Chemother (2017) 0.77
Piperacillin-tazobactam penetration into human pancreatic juice. Antimicrob Agents Chemother (2008) 0.76
Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study. BMC Pharmacol Toxicol (2016) 0.75
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials. BMC Infect Dis (2009) 0.75
Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. Eur J Clin Microbiol Infect Dis (2016) 0.75
Multidrug-resistant Pseudomonas aeruginosa endophthalmitis in a silicone oil-filled eye treated with piperacillin/tazobactam: report of a case and review of literature. Int Ophthalmol (2015) 0.75
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med (2002) 4.09
Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother (2009) 3.79
Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA (2004) 2.90
Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis (2003) 2.74
Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med (2007) 2.58
Stretching the mutant prevention concentration (MPC) beyond its limits. J Antimicrob Chemother (2003) 2.34
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs (2013) 2.33
Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother (2002) 2.32
Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis (2002) 2.26
Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob (2004) 2.24
Comparative review of the carbapenems. Drugs (2007) 2.06
In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother (2004) 2.02
Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis (2004) 1.95
Linezolid: a review of safety and tolerability. J Infect (2009) 1.95
Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med (2010) 1.86
A critical review of the fluoroquinolones: focus on respiratory infections. Drugs (2002) 1.79
Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother (2006) 1.76
The changing face of Klebsiella pneumoniae infections in the community. Int J Antimicrob Agents (2007) 1.73
Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother (2004) 1.70
Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol (2008) 1.68
Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med (2009) 1.67
Chicken as reservoir for extraintestinal pathogenic Escherichia coli in humans, Canada. Emerg Infect Dis (2012) 1.66
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother (2008) 1.66
The glycylcyclines: a comparative review with the tetracyclines. Drugs (2004) 1.64
In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (2007) 1.61
Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry and a commercial extraction system: analysis of performance, cost, and turnaround time. J Clin Microbiol (2012) 1.59
Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001. J Infect Dis (2004) 1.59
Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents (2006) 1.58
Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob Agents Chemother (2002) 1.57
The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000. Chemotherapy (2002) 1.55
Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents (2003) 1.55
In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother (2012) 1.51
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother (2010) 1.46
Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med (2009) 1.43
Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs (2009) 1.41
Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother (2013) 1.39
Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000. Antimicrob Agents Chemother (2002) 1.36
Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother (2011) 1.35
Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg Infect Dis (2005) 1.32
In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. J Clin Microbiol (2002) 1.32
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother (2009) 1.32
Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae. Scand J Infect Dis (2007) 1.29
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs (2010) 1.29
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs (2014) 1.27
The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J (2007) 1.26
The pneumococcal pilus predicts the absence of Staphylococcus aureus co-colonization in pneumococcal carriers. Clin Infect Dis (2009) 1.23
Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. Can Fam Physician (2006) 1.22
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother (2013) 1.20
Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis (2011) 1.20
Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis (2014) 1.17
Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol (2013) 1.16
Oritavancin: mechanism of action. Clin Infect Dis (2012) 1.16
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. Antimicrob Agents Chemother (2008) 1.15
Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrob Agents Chemother (2010) 1.15
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother (2008) 1.12
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother (2009) 1.12
Characterization of plasmids encoding CMY-2 AmpC beta-lactamases from Escherichia coli in Canadian intensive care units. Diagn Microbiol Infect Dis (2009) 1.11
Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents (2009) 1.11
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther (2012) 1.11
Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother (2011) 1.10
Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis (2009) 1.09
Thermostable DNase is superior to tube coagulase for direct detection of Staphylococcus aureus in positive blood cultures. J Clin Microbiol (2007) 1.08
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother (2004) 1.08
Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (2002) 1.07
Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob (2004) 1.07
Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis (2011) 1.07
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother (2003) 1.06
Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis (2008) 1.06
Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS One (2013) 1.05
Comparison of community-acquired methicillin-resistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unit. Eur J Pediatr (2006) 1.05
Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med (2005) 1.05
Anti-infective research and development--problems, challenges, and solutions. Lancet Infect Dis (2007) 1.05
Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases). Expert Opin Pharmacother (2013) 1.04
In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS). J Antimicrob Chemother (2009) 1.04
Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. J Antimicrob Chemother (2013) 1.03
Chemokine receptor 5 △32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis (2010) 1.03
Influenza epidemiology--past, present, and future. Crit Care Med (2010) 1.02
Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis (2003) 1.01
Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada. Antimicrob Agents Chemother (2003) 1.01